Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 593-602

  Berenson, James R ^a   Lichtenstein, Alan ^a   Porter, Lester ^a   Dimopoulos, Meletios A ^a   Bordoni, Roldolfo ^a   George, Sebastian ^a   Lipton, Alan ^a   Keller, Alan ^a   Ballester, Oscar ^a   Kovacs, Michael ^a   Blacklock, Hillary ^a   Bell, Richard ^a   Simeone, Joseph F ^a   Reitsma, Dirk J ^a   Heffernan, Maika ^a   Seaman, John ^a   Knight, Robert D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; DOXORUBICIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION;

EID: 6844252283     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.593     Document Type: Article

References (37)

1. Alexanian RH, Dimopoulos MA: Management of multiple myeloma. Semin Hematol 32:20-30, 1995
2. Mundy GR, Bertoline DR: Bone destruction and hypercalcemia in plasma cell myeloma. Seminars in Oncology 13:291-299, 1986
3. Belch AR, Bergsagel DE, Wilson K, et al: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9:1397-1402, 1991
4. Kyle RA, Jowsey J, Kelly PJ, et al: Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 293:1334-1338, 1975
5. Kyle RA: Multiple myeloma: Review of 869 cases. Mayo Clin Proc 50:29-40, 1975
6. Kanis JA, McCloskey EV, Taube T, et al: Rationale for the use of bisphosphonates in bone metastases. Bone 12:S13-S18, 1991 (suppl 1)
7. Fleisch H: Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism, in Brunner KW, Fleisch H, Senn H-J (eds): Recent Results in Cancer Research, vol 116: Bisphosphonates and Tumor Osteolysis. Berlin-Heidelberg, Germany, Springer-Verlag, 1989, pp 1-28
8. Stashenko P, Dewhirst FE, Peros WJ, et al: Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 138:1464-1468, 1987
9. Mundy GR: Mechanisms of osteolytic bone destruction. Bone 12:S1-S6, 1991 (suppl 1)
10. Bataille R, Chappard D, Basle M: Excessive bone resorption in human plasmacytomas: Direct induction by tumor cells in vivo. Br J Haematol 90:721-724, 1995
11. Coleman RE, Purohit OP: Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 19:79-103, 1993
12. Lahtinen R, Laakso M, Plva I, et al: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049-1052, 1992
13. Man Z, Otero AB, Rendo P, et al: Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 335:663, 1990
14. Thiebaud D, Leyuraz S, Von Fliedner V, et al: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 27:37-41, 1991
15. Purohit OP, Anthony C, Radstone CR, et al: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:554-558, 1994
16. van Holten-Verzantvoort AATM, Kroon HM, Bijvoet OLM, et al: Palliative treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
17. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Eng J Med 334:488-493, 1996
18. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842-854, 1975
19. Hayward JL, Carbone PP, Heuson J-C, et al: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289-1294, 1977
20. Holmes SJ, Whitehouse RW, Clark ST, et al: Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer 70:371-375, 1994
21. Acute Leukemia Group B, Eastern Cooperative Oncology Group. Ineffectiveness of fluoride therapy in multiple myeloma. N Eng J Med 286:1283-1288, 1972
22. Cohen HJ, Silverman HR, Tornyos K, et al: Comparison of two long-term chemotherapy regimens with or without agents to modify skeletal repair, in multiple myeloma. Blood 63:639-648, 1984
23. Lin JH: Bisphosphonates: A review of their pharmacokinetic properties. Bone 2:75-85, 1996
24. Acito A, Kasra M, Lee M, et al: The effect of intermittent administration pamidronate (APD) on the mechanical properties of canine cortical and trabecular bone. J Orthop Res 12:742-746, 1994
25. Paterson AHG, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
26. Parfitt AM: Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55:273-286, 1994
27. Feretti JL, Delgado CJ, Capozza RF, et al: Protective effects of disodium etidronate and pamidronate against the biochemical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner 20:265-276, 1993
28. Feretti JL, Cointry G, Capozza R, et al: Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats. Bone Miner 11:111-122, 1990
29. Vescio RA, Lichtenstein A, Berenson J: Myeloma, macroglobulinemia and heavy chain disease, in Haskell CM (ed): Cancer Treatment (ed 4). Philadelphia, PA, Saunders, 1995, pp 1094-1116
30. Alexanian R, Dreicer R: Chemotherapy of multiple myeloma. Cancer 53:583-588, 1994
31. Savage AD, Belson DJ, Vescio RA, et al: Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 88:105A, 1996
32. Klein B, Zhang X-G, Lu Z-Y: Interleukin-6 in multiple myeloma. Blood 85:863-872, 1995
33. Hughes DE, Wright KR, Uy HL: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487, 1995
34. Aparicio A, Gardner A, Tu Y, et al: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia (in press)
35. Sasaki A, Boyce BF, Story B, et al: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995
36. Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42446, a new, potent heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751, 1994
37. Muhlbauer RC, Bauss F, Schenk R, et al: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011, 1991